Literature DB >> 9629495

Genetic analysis of beta-thalassemia major and beta-thalassemia intermedia in Brazil.

S F Fonseca1, J Kerbauy, C Escrivao, M S Figueiredo, R Cancado, V R Arruda, S T Saad, F F Costa.   

Abstract

The development of methodologies to identify the molecular lesions responsible for different types of beta-thalassemia has made it possible to correlate these data with clinical and hematological severity. We examined DNA from 35 patients with beta-thalassemia, residents of the State of São Paulo, Brazil, for some types of genetic modifying factors: beta-thalassemia mutations, the upstream Xmnl GY-globin gene polymorphisms, and alpha-globin gene deletions. Additionally, the beta-like gene cluster haplotypes and the presence of the AYT variant were studied. The following mutations were present in the 70 chromosomes studied: 54.3% codon 39 (C-->T) (beta degree); 18.6% IVS-I-6 (T-->C) (beta+); 18.6% IVS-I-110 (G-->A) (beta+), and 4.3% IVS-I-1 (G-->T) (beta degree). Haplotype II was associated with the nonsense mutation at codon 39, haplotype I with the IVS-I-110 and codon 39 mutations, and haplotypes VI and VII with the IVS-I-6 mutation. The Xmnl polymorphism was detected in three out of 31 patients studied. No alpha-thalassemia was detected among the thalassemia intermedia patients. The AYT variant was present in 87.1% of 31 thalassemia patients and was associated with the codon 39/haplotype II and IVS-I-6/haplotype VI mutations. This is the first study of the Brazilian population that has analyzed the beta-thalassemia mutations and other molecular variants, and has correlated them with the clinical manifestations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9629495     DOI: 10.3109/03630269809113134

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  5 in total

1.  Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics.

Authors:  André R Belisário; Anna B Carneiro-Proietti; Ester Cerdeira Sabino; Aderson Araújo; Paula Loureiro; Cláudia Máximo; Miriam V Flor-Park; Daniela D O W Rodrigues; Mina Cintho Ozahata; Christopher McClure; Rosimere Afonso Mota; Isabel C Gomes Moura; Brian Custer; Shannon Kelly
Journal:  Hemoglobin       Date:  2020-03-16       Impact factor: 0.849

2.  Characterization of beta-thalassemia mutations in patients from the state of Rio Grande do Norte, Brazil.

Authors:  Zama Messala Luna da Silveira; Maria das Vitórias Barbosa; Thales Allyrio Araújo de Medeiros Fernandes; Elza Miyuki Kimura; Fernando Ferreira Costa; Maria de Fátima Sonati; Ivanise Marina Moretti Rebecchi; Tereza Maria Dantas de Medeiros
Journal:  Genet Mol Biol       Date:  2011-07-01       Impact factor: 1.771

3.  Compound heterozygous state of β-thalassemia with IVS1-5 (G→C) mutation and Indian deletion-inversion Gγ(Aγδβ)(0)-thalassemia in eastern India.

Authors:  Snehadhini Dehury; Prasanta Purohit; Satyabrata Meher; Kishalaya Das; Siris Patel
Journal:  Rev Bras Hematol Hemoter       Date:  2015-05-12

4.  Molecular characterization of β-thalassemia intermedia in the West Bank, Palestine.

Authors:  Rashail Faraon; Mahmoud Daraghmah; Fekri Samarah; Mahmoud A Srour
Journal:  BMC Hematol       Date:  2019-02-18

5.  Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment.

Authors:  Fabia Neves; Osvaldo Alves Menezes Neto; Larissa Bueno Polis; Sarah Cristina Bassi; Denise Menezes Brunetta; Ana Cristina Silva-Pinto; Ivan Lucena Angulo
Journal:  Rev Bras Hematol Hemoter       Date:  2012
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.